KOL thinks Apellis Pharmaceuticals (APLS) issues with Syfovre 'likely solvable' - TD Cowen

TD Cowen analyst Phil Nadeau weighed in on Apellis Pharmaceuticals (NASDAQ: APLS) after shares fell 38% after six cases of retinal vasculitis have been reported with Syfovre.

The analyst commented, "During TD Cowen Rounds @ Cleveland Clinic today we discussed the situation with a retinal KOL. He thinks understanding the cause and mitigating the risk will be key to Syfovre's uptake and potential. His initial guess is that the cause is due to manufacturing or delivery and not mechanism, implying to us the issue is likely solvable."

The analyst reiterated an Outperform rating and $95.00 price target on APLS.

For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.

Shares of Apellis Pharmaceuticals closed at $84.50 yesterday.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• TD Cowen: 'CABA appears well-positioned to scale commercially with minimal capital investment'